Role of anthracycline and comprehensive geriatric assessment for elderly patients with diffuse large B-cell lymphoma
Open Access
- 16 November 2017
- journal article
- review article
- Published by American Society of Hematology in Blood
- Vol. 130 (20) , 2180-2185
Abstract
Survival outcome for elderly patients with newly diagnosed diffuse large B-cell lymphoma remains suboptimal in the rituximab era. In this systematic review, we summarize available evidence relevant to the inclusion of anthracycline in upfront chemoimmunotherapy for these elderly patients and highlight the need of prospective clinical trials. With limited prospective data, we find that pretreatment comprehensive geriatric assessment accurately predicts survival and treatment-related toxicities, suggesting its potential role in guiding overall treatment decision-making.Keywords
This publication has 47 references indexed in Scilit:
- Modulated Chemotherapy According to Modified Comprehensive Geriatric Assessment in 100 Consecutive Elderly Patients with Diffuse Large B-Cell LymphomaThe Oncologist, 2012
- Tailored Therapy in an Unselected Population of 91 Elderly Patients with DLBCL Prospectively Evaluated Using a Simplified CGAThe Oncologist, 2012
- Treatment of the elderly patient with diffuse large B cell lymphomaBritish Journal of Haematology, 2012
- The proportion of activated B-cell like subtype among de novo diffuse large B-cell lymphoma increases with ageHaematologica, 2011
- How I treat elderly patients with diffuse large B-cell lymphomaBlood, 2010
- A comprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large cell lymphoma patients who benefit from aggressive therapyCancer, 2009
- Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'AdulteJournal of Clinical Oncology, 2005
- Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHLBlood, 2004
- CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell LymphomaNew England Journal of Medicine, 2002
- A Predictive Model for Aggressive Non-Hodgkin's LymphomaNew England Journal of Medicine, 1993